Form 4: Nuvation Bio Director Kim Blickenstaff Receives Significant Stock Option Grant

Sentiment:

Insider Transaction Report 23 May 2025 4:05 PM

Nuvation Bio Inc. Director Kim D. Blickenstaff was granted 292,983 stock options with an exercise price of $2.03, aligning executive incentives with shareholder value.

Summary

Kim D. Blickenstaff, a Director of Nuvation Bio Inc. (NUVB), was granted 292,983 stock options.
The stock options have an exercise price of $2.03 per share.
The grant date for these options was May 21, 2025.
The options are set to vest 100% on the earlier of (i) the one-year anniversary of the grant date (May 21, 2026) or (ii) the next shareholder annual meeting.
Vesting is contingent upon the Reporting Person's continuous service through the applicable vesting date.
The stock options have an expiration date of May 20, 2035.
The underlying securities for these options are 292,983 shares of Nuvation Bio Inc. Class A Common Stock.
Following this transaction, Kim D. Blickenstaff beneficially owns 292,983 derivative securities directly.
A Power of Attorney dated May 22, 2025, was filed, authorizing Philippe Sauvage, Moses Makunje, and Stephen Dang of Nuvation Bio Inc. to prepare and file SEC forms on behalf of Kim Blickenstaff.

Sentiment

Score: 7

Explanation: The sentiment is positive as the grant of stock options to a director is a standard practice that aligns management incentives with shareholder interests, indicating continued commitment from the director. It does not suggest any negative operational or financial issues.

Positives

The grant of stock options to a director aligns their financial interests directly with the long-term performance and shareholder value creation of Nuvation Bio Inc.
The vesting schedule encourages the director's continued service and commitment to the company's success.

Future Outlook

The vesting schedule of the stock options, tied to continuous service, indicates an expectation of the director's ongoing involvement and commitment to Nuvation Bio Inc. for at least the next year or until the next shareholder annual meeting.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to incentivize long-term performance and align the interests of leadership with those of shareholders. This filing reflects a standard compensation mechanism for board members.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Administrative Authorization	A Power of Attorney was executed, granting specific individuals the authority to prepare and file SEC forms (including Forms 3, 4, and 5) on behalf of Director Kim Blickenstaff. This streamlines compliance with Section 16(a) reporting requirements.	05/22/2025	This is a standard administrative measure that enhances efficiency in regulatory filings for the director, ensuring timely compliance with SEC reporting obligations.

Related Party Transactions

The grant of stock options to Kim D. Blickenstaff, a director of Nuvation Bio Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

Shareholders: The option grant aligns the director's financial incentives with the company's stock performance, potentially benefiting shareholders if the stock price increases.
Employees: No direct impact on general employees is indicated by this filing.

Next Steps

The director's continuous service is required for the stock options to vest on the specified dates (May 21, 2026, or the next shareholder annual meeting).

Key Dates

Date	Description
05/21/2025	Date of earliest transaction (grant date of stock option).
05/22/2025	Date of Power of Attorney.
05/23/2025	Date the Form 4 was signed.
05/21/2026	One-year anniversary of the grant date, a potential vesting date for the stock options.
05/20/2035	Expiration date of the stock options.

Recommendation

hold

Keywords

Nuvation Bio, NUVB, Stock Option, Insider Transaction, Form 4, SEC Filing, Director Compensation, Equity Grant, Vesting, Corporate Governance

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.